Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer

Among patients with non-small cell lung cancer (NSCLC), it is estimated that between 3 –5% have anaplastic lymphoma kinase (ALK)-positive disease [1] and 1.7–2.2% have ROS1 gene rearrangement [2–4]. Targeting ALK using tyrosine kinase inhibitors (TKIs) has dramatically improved the prognosis of patients with ALK-rearranged NSCLC [5]. However, most patients relapse on first or se cond-generation ALK TKI therapy within months to a few years following acquired resistance [6–8]. The third-generation ALK and ROS1 inhibitor lorlatinib (PF-06463922) was developed to inhibit resistant ALK mutations, including the difficult to treat ALK G1202R mutation, and to optimally penetrate the blood–brain barrier[6].

Source: Lung Cancer - March 8, 2020 Category: Cancer & Oncology Authors: Solange Peters, Alice T. Shaw, Benjamin Besse, Enriqueta Felip, Benjamin J. Solomon, Ross A. Soo, Alessandra Bearz, Shirish M. Gadgeel, Chia-Chi Lin, Steven Kao, Takashi Seto, Elizabeth T. Masters, Antonello Abbattista, Jill S. Clancy, Holger Thurm, Arlen Source Type: research